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Abstract 
Background: Subjects with chronic obstructive pulmonary disease (COPD) are prone to accelerated decay of muscle 
strength and mass with advancing age. This is believed to be driven by disease-inherent systemic pathophysiologies, 
which are also assumed to drive muscle cells into a state of anabolic resistance, leading to impaired abilities to adapt 
to resistance exercise training. Currently, this phenomenon remains largely unstudied. In this study, we aimed to 
investigate the assumed negative effects of COPD for health- and muscle-related responsiveness to resistance training 
using a healthy control-based translational approach.
Methods: Subjects with COPD (n = 20, GOLD II-III,  FEV1predicted 57 ± 11%, age 69 ± 5) and healthy controls (Healthy, 
n = 58,  FEV1predicted 112 ± 16%, age 67 ± 4) conducted identical whole-body resistance training interventions for 
13 weeks, consisting of two weekly supervised training sessions. Leg exercises were performed unilaterally, with one 
leg conducting high-load training (10RM) and the contralateral leg conducting low-load training (30RM). Measure-
ments included muscle strength  (nvariables = 7), endurance performance  (nvariables = 6), muscle mass  (nvariables = 3), mus-
cle quality, muscle biology (m. vastus lateralis; muscle fiber characteristics, RNA content including transcriptome) and 
health variables (body composition, blood). For core outcome domains, weighted combined factors were calculated 
from the range of singular assessments.
Results: COPD displayed well-known pathophysiologies at baseline, including elevated levels of systemic low-grade 
inflammation ([c-reactive  protein]serum), reduced muscle mass and functionality, and muscle biological aberrancies. 
Despite this, resistance training led to improved lower-limb muscle strength (15 ± 8%), muscle mass (7 ± 5%), muscle 
quality (8 ± 8%) and lower-limb/whole-body endurance performance (26 ± 12%/8 ± 9%) in COPD, resembling or 
exceeding responses in Healthy, measured in both relative and numeric change terms. Within the COPD cluster, lower 
 FEV1predicted was associated with larger numeric and relative increases in muscle mass and superior relative improve-
ments in maximal muscle strength. This was accompanied by similar changes in hallmarks of muscle biology such 
as rRNA-content↑, muscle fiber cross-sectional area↑, type IIX proportions↓, and changes in mRNA transcriptomics. 
Neither of the core outcome domains were differentially affected by resistance training load.
Conclusions: COPD showed hitherto largely unrecognized responsiveness to resistance training, rejecting the notion 
of disease-related impairments and rather advocating such training as a potent measure to relieve pathophysiologies.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
associated with impaired cardiorespiratory fitness and 
decreased skeletal muscle mass and strength [1], leading 
to reduced levels of daily activity and reduced quality of 
life [2, 3]. This deterioration is accompanied by systemic 
co-morbidities such as reduced levels of testosterone [4], 
vitamin D [5, 6] and oxygen saturation levels [7], and ele-
vated levels of low-grade inflammation [8], which argua-
bly leaves COPD subjects in a state of anabolic resistance 
[9], resulting in impaired abilities to adapt to exercise 
training [10–12]. In particular, these pathophysiologies 
are believed to impair adaptations to resistance training, 
which represent the most potent intervention for improv-
ing muscle functions [13–16] and preventing escalation 
into late-stage morbidities such as pulmonary cachexia 
[17]. Despite this general belief, the presence of anabolic 
resistance in COPD subjects and its consequences for 
responses to resistance training remain circumstantial. A 
mere single study has compared functional and biologi-
cal adaptations to resistance training between COPD and 
healthy controls (ISRCTN ID: 22764439) [18–20], and as 
such was limited by a relatively short training interven-
tion (8  weeks), a rather untraditional training protocol 
with little clinical and practical relevance, and a limited 
selection of outcome variables. Whereas the study failed 
to disclose COPD-related impairments in muscle 
strength and growth responses, it seems premature to 
dismiss the notion that COPD pathophysiologies may 
impair training responsiveness [21], and there is clearly 
need for further study.
The primary aim of the present study was to investigate 
the assumed negative effects of COPD pathophysiolo-
gies on physiological responses to 13 weeks of resistance 
training, with emphasis on a broad range of muscle func-
tional and biological outcome measures. The second-
ary aim was to investigate inherent differences between 
COPD and Healthy, and to investigate the interaction 
between two different resistance training modalities and 
training responsiveness (high-load vs. low-load resist-
ance training; 10 vs 30 repetitions maximum, RM).
Methods
For in-depth description of study protocols and methods, 
including description of a placebo-controlled vitamin 
 D3 supplementation protocol (randomized clinical trial), 
see Figs.  1, 2 and clinicaltrial.gov (ClinicalTrials.gov 
Identifier: NCT02598830). The study was designed and 
scaled to allow elucidation of the effects of vitamin  D3 
supplementation for adaptations to resistance training, 
as well as to compare training responsiveness between 
COPD and Healthy. The vitamin  D3 perspective is cov-
ered in detail elsewhere [22].
Study ethics and participants
The study was approved by the Regional Commit-
tee for Medical and Health Research Ethics (refer-
ence no. 2013/1094), preregistered at clinicaltrials.gov 
(NCT02598830), and conducted according to the Decla-
ration of Helsinki. All participants were informed about 
the potential risks and discomforts associated with the 
study and gave their informed consent prior to study 
enrolment.
Persons with either medical diagnosis of stable COPD 
(GOLD grade II-III [23], predicted forced expiratory 
volume in first second  (FEV1) between 80%-30%,  FEV1/
forced vital capacity (FVC) < 70% after reversibility test-
ing, n = 24, age 70 ± 5) or normal lung function (n = 70, 
age 67 ± 5) received the study intervention. For study 
flow chart, see Fig. 1. For baseline characteristics of the 
participants completing the study, see Table 1.
Study conduct
COPD and Healthy conducted identical 13-week resist-
ance training protocols, consisting of two weekly full-
body training sessions (Fig. 2) with primary focus on leg 
exercises. The leg exercises, i.e. leg press, knee extension 
and knee flexion, were performed unilaterally in that 
consecutive order, with one of the legs of each participant 
being randomly assigned to perform three sets of 10RM 
(high-load) and the contralateral leg to perform three 
sets of 30RM (low-load). For each exercise, all three sets 
for one leg were conducted before the other leg was exer-
cised. This unilateral training protocol served two pur-
poses: i) to circumvent issues relating to conduction of 
training with two-legged exercises in COPD [24] and ii) 
to investigate the relative efficacy of two different train-
ing modalities (10RM vs 30RM). Exercises and sets were 
separated by ~ 2 min of rest, with individual adjustments 
being made whenever participants needed a longer rest 
period. All sessions were supervised by qualified per-
sonnel and lasted for ~ 60  min. The effectiveness of the 
training intervention was assessed as a wide range of out-
come measures (Fig.  2), including multiple assessments 
Trial registration: ClinicalTrials.gov ID: NCT02598830. Registered November 6th 2015, https:// clini caltr ials. gov/ ct2/ 
show/ NCT02 598830
Keywords: Anabolic resistance, COPD, Pathophysiology, Skeletal muscle, Strength training, Training load
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Fig. 1 CONSORT flow chart of the study. The study was conducted as a double-blind randomized clinical trial, with the primary aim of investigating 
the effects of vitamin  D3 supplementation on resistance training-associated adaptations in a mixed population of older subjects, including both 
COPD and healthy control subjects (COPD and Healthy, respectively) (ClinicalTrials.gov Identifier: NCT02598830). Vitamin  D3 supplementation did 
not affect any primary or secondary outcome, and no conditional effects were observed for COPD vs Healthy in that context [22]. In the present 
study, the main purpose was to compare the effects of resistance training between COPD and Healthy participants (number of participants 
completing the study protocol; n COPD = 20; n Healthy = 58)
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of endurance performance, muscle strength and mass, 
measures of work economy/efficiency, and collection of 
blood and vastus lateralis biopsies (both legs) (Fig. 2).
Blood and muscle measurements
Prior to collection of blood and muscle biopsies, par-
ticipants were instructed to attend an overnight fast and 
to avoid heavy physical activity for the last 48  h. Blood 
samples were analyzed for serum concentrations of hor-
mones, lipids, and markers of iron metabolism and tissue 
damage, as previously described [22]. Muscle biopsies 
were analyzed for muscle fiber type proportions, myonu-
clei content, muscle fiber cross-sectional area (CSA), and 
rRNA and mRNA content (total RNA, rRNA subspecies, 
myosin heavy chain isoforms I, IIA and IIX, and whole-
genome transcriptome), as previously described [22, 25, 
26]. Transcriptome analysis was restricted to a subset of 
participants (COPD, n = 19 (n prior to resistance train-
ing, 19; n after 3 ½ week of training, 17; n post resistance 
training, 19); Healthy, n = 34 for all time points), selected 
based on quality of total RNA samples (RNA Qual-
ity Indicator > 7.0, avg 9.0 ± 0.5), with participants with 
COPD and participants with complete sets of muscle 
biopsies being prioritized.
Data analyses and statistics
Analyses were conducted per-protocol, due to the trans-
lational approach of the study. For continuous variables, 
linear mixed-effects models were used to examine differ-
ences between COPD and Healthy, both at baseline and 
as responses to resistance training. For the latter, rela-
tive and numeric changes from baseline were defined as 
dependent variables, with COPD/Healthy being defined 
as the fixed effect. Effects of sex were implemented into 
the models. Analyses included evaluation of interaction 
effects with training load (repeated measures/observa-
tions from high- and low-load training legs were added 
to the model for unilateral outcome measures) and 
sex. Time effects were examined using mixed model-
ling, with the dependent variable and time points being 
defined as repeated measures/observations. To describe 
the relationship between COPD severity and training 
responses, simple linear regression analyses of core out-
come domains change scores and predicted  FEV1 were 
performed.
For non-continuous variables, generalized linear 
mixed-effects models (GLMMs) were used (binomial 
GLMMs, immunohistochemical fiber type proportion 
analyses; negative binomial GLMMs, rRNA/mRNA con-
tent in quantitative real-time polymerase chain reaction 
(qPCR) and transcriptome analyses). For transcriptome 
analyses, gene counts were modelled using the total 
library size as a fixed effect [27], together with sex and 
study conditions (time points and COPD/Healthy). 
Models were iteratively fitted using glmmTMB [28]. 
Genes were regarded as differentially expressed when 
the numeric  log2 fold-change/difference were greater 
than 0.5 and the adjusted p-value (false discovery rate 
adjusted per model coefficient) was below 5% [25]. More-
over, enrichment analyses were performed on Hallmark, 
Fig. 2 Schematic overview of the study protocol, including its time line (A; ‡indicates the defined baseline measurement for the specific outcome 
measure), training volumes during the resistance training (RT) intervention (B), perceived exertion (Borg RPE, 6–20) reported after training sessions 
(C), and relative training loads (% of 1RM) during the training period (D). Training volume is presented as average increases in per-session for 
lower-body appendices from the first week of training (kg . repetitions; high-load (10RM) and low-load (30RM) leg press and knee extension 
combined). Training loads in numeric values (kg) during the resistance training intervention are provided in Additional file 1: Fig. S1. COPD, 
participants diagnosed with chronic obstructive pulmonary disease; Healthy, healthy control participants; *statistical different from 1th training 
week; #statistical difference between COPD and Healthy. Data are presented as means with 95% confidence limits. Methodological notes on 
retrieval of outcome measures: i) Lung function. Spirometry testing was performed following the guidelines from the American Thoracic Society 
and the European Respiratory Society [72]. Participants with COPD were tested before and after inhalation of two bronchodilators (salbutamol/
ipratropiumbromid). ii) Muscle strength and performance (STR and Musc. perf ). Muscle strength was assessed as one-repetition maximum (1RM) 
in unilateral knee extension and leg press, bilateral chest press, and handgrip. Muscle performance was defined as the number of repetitions 
achieved at 50% of pre-study 1RM and was assessed using unilateral knee extension and bilateral chest press. Isokinetic unilateral knee-extension 
torque was tested at three angular speeds (60°, 120° and 240°.  sec−1; Humac Norm, CSMi, Stoughton, MA, USA). iii) One-legged cycling and 
bicycling performance (1-LC and  VO2max). Participants conducted one-legged cycling tests (Excalibur Sport, Lode BV, Groningen, the Netherlands) 
to assess  O2-costs and mechanical efficiency [73] during submaximal cycling, and maximal one-legged oxygen consumption (V̇O2max) and 
maximal workload. Maximal two-legged cycling V̇O2max and workload were tested on a separate day. Oxygen consumption was measured using 
the JAEGER Oxycon Pro™ system (Carefusion GmbH, Höchberg, Germany). iv) Functional performance (Func.). Functional tests were conducted 
as the maximal number of sit-to-stands during one minute (seat height: 45 cm) and as the number of steps onto a 20 cm step box during 6 min. 
v) Health-related quality of life (SF-36 and CAT). All participants completed the Short Form (36-item) Health Survey (SF-36). COPD participants 
also completed the COPD Assessment Test (CAT) questionnaire. vi) Muscle thickness and body mass composition (US/DXA). Muscle thickness 
of m. vastus lateralis and m. rectus femoris were measured using B-mode ultrasonography (SmartUs EXT-1 M, Telemed, Vilnius, Lithuania). Body 
mass composition was measured using dual-energy X-ray absorptiometry (DXA; Lunar Prodigy, GE Healthcare, Madison, WI, USA). At pre study, 
all participants completed a questionnaire regarding regular weekly activity habits. The results (time spent for different activities) were translated 
into energy expenditure  (kcals.week−1) during activities using number of metabolic equivalents provided in Jetté et al. [74]. During week 11, all 
participants conducted a dietary registration, in which they logged their dietary intake for three days, including one weekend day
(See figure on next page.)
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Fig. 2 (See legend on previous page.)
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Table 1 Characteristics of the participants completing the study
COPD Healthy Sex-adjusted estimated difference
COPD – Healthy (95% CI) P-value
General
 Participants, completing (no. ♂/♀) / dropouts† (no.) 20 (12/8) / 2 58 (21/37) / 2 – –
 Age (years) 69 ± 5 (range, 60–79) 67 ± 4 (range, 57–78) 2 (0, 5) 0.049*
 Height (cm) 171 (10) 170 (10) −3 (−6, 0) 0.056
 Body mass (kg) 73 (18) 76 (16) −7 (−14, 0) 0.061
 Body mass index  (kg.  m2) 25 (5) 26 (5) −2 (−4, 1) 0.237
 Pack-years (no.) 30 (16) 6 (10) 23 (17, 29)  < 0.001*
 GOLD grade (no. of grade II/III) 15/5 – – –
 COPD Assessment Test™ score (0–40) 16.6 (6.8) – – –
 Self-reported conception of health (0–10) 4.9 (1.2) 6.7 (1.6) − 1.7 (− 2.5, − 0.7) 0.001*
Physical activity level
 Household work  (kcals.week−1) 1754 (2062) 1866 (2201) − 164 (− 1322, 995) 0.779
 Recreational activities  (kcals.week−1) 2512 (2619) 2654 (1841) 188 (− 862, 1237) 0.723
 Total activity  (kcals.week−1) 4266 (4036) 4520 (2837) 24 (− 1657, 1704) 0.978
Pulmonary function
 FVC (L) 3.2 (0.9) 3.6 (0.9) − 0.7 (− 1.0, − 0.4)  < 0.001*
 FVC (% predicted) 97 (19) 112 (16) − 13 (− 22, − 4) 0.003*
  FEV1  (L
.  sec−1) 1.5 (0.4) 2.7 (0.7) − 1.4 (− 1.6, − 1.2)  < 0.001*
  FEV1 (% predicted) 57 (11) 104 (16) − 47 (− 55, − 39)  < 0.001*
  FEV1/FVC (%) 47 (8) 75 (6) − 28 (− 31, − 24)  < 0.001*
 PEF  (L.  sec−1) 5.0 (1.6) 7.7 (2.1) − 3.4 (− 4.1, − 2.7)  < 0.001*
Pulmonary medication
  B2-agonists (no.) 17/20 – – –
 Muscarinic agonists (no.) 15/20 – – –
 Medication containing both  b2-agonist and glucocorticoid 
(no.)
10/20 – – –
Body composition
 Total lean mass (kg) ♂, 53 (4); ♀, 36 (6) ♂, 60 (5); ♀, 41 (4) − 6 (− 9, − 4)  < 0.001*
 Whole-body bone mineral density  (g.  cm2) ♂, 1.2 (0.1); ♀, 1.0 (0.2) ♂, 1.3 (0.1); ♀, 1.1 (0.1) − 0.1 (− 0.2, − 0.0) 0.007*
 Total fat mass (kg) ♂, 26 (10); ♀, 27 (15) ♂, 26 (9); ♀, 25 (10) 1 (− 5, 7) 0.703
 Visceral fat (kg) ♂, 1.9 (1.3); ♀, 1.0 (0.7) ♂, 1.7 (1.0); ♀, 0.8 (0.7) 0.2 (− 0.3, 0.7) 0.412
Lower−-body muscle strength
 1RM leg press (kg) ♂, 121 (35); ♀, 82 (21) ♂, 152 (27); ♀, 124 (25) − 36 (− 47, − 26)  < 0.001*
 1RM knee extension (kg) ♂, 21 (4); ♀, 11 (4) ♂, 31 (5); ♀, 16 (3) − 7 (− 9, − 5)  < 0.001*
 Peak torque knee extension 60° .  sec−1 (Nm) ♂, 127 (34); ♀, 80 (25) ♂, 160 32); ♀, 101 (16) − 27 (− 36, − 17)  < 0.001*
 Peak torque knee extension 180° .  sec−1 (Nm) ♂, 83 (25); ♀, 47 (17) ♂, 102 (23); ♀, 62 (11) − 19 (− 28, − 9)  < 0.001*
 Peak torque knee extension 240° .  sec−1 (Nm) ♂, 68 (20); ♀, 38 (14) ♂, 84 (20); ♀, 50 (9) − 15 (− 20, − 9)  < 0.001*
 Lower-body muscle strength factor (AU) ♂, 0.5 (0.1); ♀, 0.3 (0.1) ♂, 0.6 (0.1); ♀, 0.4 (0.1) − 0.1 (− 0.2, − 0.1)  < 0.001*
Lower-body muscle mass measures
 Leg lean mass (kg) ♂, 18 (2); ♀, 12 (3) ♂, 20 (2); ♀, 14 (2) − 3 (− 4, − 2)  < 0.001*
 M. vastus lateralis thickness (mm) ♂, 20 (3); ♀, 18 (5) ♂, 22 (3); ♀, 20 (3) − 2 (− 3, − 1) 0.002*
 M. rectus femoris thickness (mm) ♂, 13 (4); ♀, 10 (3) ♂, 16 (4); ♀, 15 (4) − 4 (− 5, − 2)  < 0.001*
 Lower-body muscle mass factor (AU) ♂, 0.6 (0.1); ♀, 0.5 (0.1) ♂, 0.7 (0.1); ♀, 0.6 (0.1) − 0.1 (− 0.2, − 0.1)  < 0.001*
Endurance measures
 Maximal power output one-legged cycling (W) ♂, 73 (13); ♀, 48 (17) ♂, 148 (28); ♀, 108 (21) − 67 (− 77, − 58)  < 0.001*
 Maximal power output two-legged cycling (W) ♂, 118 (38); ♀, 75 (32) ♂, 252 (48); ♀, 167 (32) − 113 (− 134, − 92)  < 0.001*
 Maximal oxygen consumption (mL  O2
.  kg−1.  min−1) ♂, 20 (5); ♀, 16 (5) ♂, 35 (7); ♀, 28 (6) − 14 (− 18, − 10)  < 0.001*
 6 min step test (maximal number of steps) ♂, 123 (35); ♀, 115 (44) ♂, 208 (41); ♀, 196 (38) − 83 (− 105, − 61)  < 0.001*
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Kyoto encyclopedia of Genes and Genomes (KEGG) and 
Gene Ontology gene sets, using two approaches. First, 
a non-parametric rank test was performed based on 
gene-specific minimum significant differences. Second, 
a gene set enrichment analysis (GSEA) was performed 
to quantify directional regulation of the gene set. GSEA 
was performed using the fgsea package [29]. Consen-
sus results (i.e. when both the non-directional rank test 
and the directional GSEA turned out significant) were 
interpreted as having greater biological meaning, while 
Hallmark was interpreted as contributing with the most 
meaningful stand-alone interpretation, as it reduces the 
analytical noise by taking into account genes that over-
lap between gene sets [30]. All gene sets were retrieved 
using the molecular signature database (version 7.1.) [31]. 
Overview of gene enrichment analyses with exact p-val-
ues are presented in Additional file 1: Table S3. A reposi-
tory containing all transcriptome data and scripts used 
for transcriptome and enrichment analyses are available 
at https:// github. com/ dhamm arstr om/ rnaseq- copd.
For all immunohistochemical variables, statistical 
models were weighted for numbers of counted fibers per 
biopsy. This was done to account for the reduced reliabil-
ity accompanying fewer observations/fibers [22].
To achieve reliable assessment of core outcome 
domains, and thus to lower the risk of statistical errors, 
combined factors were calculated for outcome meas-
ures relating to lower-body muscle strength (composed 
of values from the variables 1RM knee extension and leg 
press (I), and peak torque for knee extension at 60, 180 
and 240°/sec (II)), lower-body muscle mass (leg lean mass 
(I) and vastus lateralis and rectus femoris thickness (II)), 
one-legged endurance performance (maximal workload 
achieved during one-legged cycling (I) and number of 
repetitions at 50% of 1RM knee extension at pre-study 
(II)) and whole-body endurance performance (maximal 
workload achieved during bicycling (I), maximal number 
of steps achieved in a 6-min test (II), and maximal num-
ber of sit-to-stands in a 1-min test (III)), as previously 
described [22]. During factor calculation, each of the 
underlying variables were normalized to the participant 
with the highest value recorded during the RCT, resulting 
in individual scores ≤ 1. Thereafter, outcome domain fac-
tors were calculated as the mean of the normalized val-
ues for each variable for each participant. For details, see 
Additional file 1: Table S1.
In all mixed-effects models, a single random effect was 
used, giving each participant an individual intercept. Sta-
tistical significance was set to p < 0.05. In both text and 
figures, data are presented as adjusted, marginal means, 
with or without 95% confidence intervals, unless other-
wise stated. Statistical analyses were performed using 
SPSS Statistics package version 24 (IBM, Chicago, IL, 
USA) (statistical models with continuous variables, as 
well as immunohistochemical fiber type proportions) and 
R software [32] (statistical analyses of rRNA/mRNA con-
tent). Figures were made using Prism Software (Graph-
Pad 8, San Diego, CA, USA) and R software [32].
Results and discussion
Baseline characteristics: COPD vs Healthy
Exercise capacity, body composition and muscle and blood 
biology
At baseline (prior to onset of training), COPD displayed 
impaired exercise capacity compared to Healthy, as 
expected from previous studies [3, 18, 20, 33]. This was 
evident as impaired whole-body performance (range: 
−  41 −  54%, Table  1), and lower-body unilateral mus-
cle strength and endurance performance (−  17 −  30%, 
Table 1), presumably reflecting the cardiorespiratory and 
muscular limitations inherent to the condition [21], and 
likely being decoupled from levels of habitual physical 
Table 1 (continued)
COPD Healthy Sex-adjusted estimated difference
COPD – Healthy (95% CI) P-value
 1 min sit-to-stand test (maximal number) ♂, 21 (5); ♀, 21 (6) ♂, 30 (5); ♀, 29 (5) − 9 (− 12, − 6)  < 0.001*
  nrepetitions at 50% of 1RM knee  extensionpre study ♂, 19 (5); ♀, 17 (5) ♂, 23 (6); ♀, 20 (7) − 4 (− 6, − 1) 0.005*
 One-legged endurance performance factor (AU) ♂, 0.2 (0.0); ♀, 0.2 (0.0) ♂, 0.4 (0.1); ♀, 0.3 (0.1) − 0.2 (− 0.2, − 0.1)  < 0.001*
 Whole-body endurance performance factor (AU) ♂, 0.4 (0.1); ♀, 0.3 (0.1) ♂, 0.7 (0.1); ♀, 0.6 (0.1) − 0.3 (− 0.3, − 0.2)  < 0.001*
COPD, participants diagnosed with chronic obstructive pulmonary disease; Healthy, healthy control participants; ♂, males; ♀, females; †, dropouts during the training 
period; *study clusters are significantly different from each other (p < 0.05); GOLD, Global Initiative for Chronic Obstructive Lung Disease; pack-years, (number of 
cigarettes smoked per day/20) × number of years smoked; FVC, forced vital capacity;  FEV1, forced expiratory volume in one second; PEF, peak expiratory flow; 1RM, 
one repetition maximum; Nm, newton-meter; AU, arbitrary units. Data mainly presented as mean (SD), and sex-adjusted estimated mean differences between 
study clusters (95% CI). For core outcome domains, i.e. lower-body muscle strength, lower-body muscle mass, one-legged endurance performance and whole-body 
endurance performance, factors were calculated. Briefly, each factor was calculated using multiple singular outcome measures, where each of these variables were 
normalized to the participant with the highest value recorded during the study, resulting in individual scores ≤ 1. Thereafter, outcome domain factors were calculated 
as the mean of the normalized values for each variable for each subject (see Additional file 1: Table S1 for complete overview over calculations and composition of 
each factor)
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activity, as no difference was observed between study 
clusters prior to onset of the study (Table  1). Alongside 
the reduced exercise capacity, COPD had less lean body 
mass than Healthy (− 13%, Table 1), with 45% of COPD 
showing signs of sarcopenia, as defined by Baumgartner 
et al. [34]. In the legs, this was manifested as -16% reduc-
tions in leg-specific lean mass and −  9/−  24% smaller 
vastus lateralis/rectus femoris thicknesses (Table  1), 
offering potential explanations for the impaired maximal 
leg muscle strength. Of note, for markers of muscle mass 
the difference between study clusters was likely related 
to traits inherent to the COPD condition rather than 
to the small age difference between COPD and Healthy 
(−  2  years; Table  1), as the magnitude of the difference 
would have implied an annual loss of ~ 2.6 kg lean mass 
per year in the COPD cluster, deviating substantially 
from the expected loss in this age group (~ 0.5  kg per 
year) [35].
For muscle biological variables, the COPD cluster 
showed lowered proportions of type I fibers and greater 
proportions of type IIA and IIX muscle fibers in vas-
tus lateralis compared to Healthy (32/23% vs 13/9%, 
respectively), corroborating with previous studies 
[36, 37]. For type I fibers, COPD showed larger CSA 
(12%, Table  2) and larger myonuclear domain (CSA 
per myonuclei; 20%, Table 2), with no such differences 
being observed for type II fibers. This contrasts previ-
ous studies, who have reported smaller or similar CSA 
in type I fibers in COPD compared to Healthy [33, 38, 
39], and may point to a compensatory mechanism for 
the likely loss of motor units in COPD subjects [40], 
whereby reduced quantities of muscle fibers are com-
pensated for by increased sizes of remaining fibers, as 
previously reported in rodents [41]. These observed 
differences in muscle fiber characteristics were accom-
panied by differences in RNA expression. Although 
COPD and Healthy showed similar levels of total RNA 
and rRNA expression per amount of muscle tissue at 
baseline (Table  2), COPD displayed distinct whole-
genome transcriptome profiles, with 227 genes being 
differentially expressed compared to Healthy (151↑ and 
76↓; Fig. 3A and Additional file 1: Table S2). Hallmark 
enrichment analysis revealed lower expression of genes 
involved in oxidative phosphorylation (consensus, i.e. 
agreement between GSEA and rank-based analyses), 
corroborating with the lower type I proportion, as well 
as greater expression of genes involved in regulation 
of myogenesis (Rank) (Fig.  3A, B, Table  3; confirmed 
by gene ontology analysis, Additional file  1: Table  S3), 
which may be related to the pathophysiological eleva-
tion of protein turnover in COPD [42, 43].
For blood variables, the COPD cluster showed ele-
vated levels of low-grade inflammation compared to 
Healthy, measured as levels of c-reactive protein prior 
to the study (5.0 vs 1.6   mg.L−1, p = 0.001, data not 
shown; baseline (i.e. prior to resistance training), 5.0 vs 
1.6  mg.L−1, p = 0.053, Table 4), as expected from previ-
ous studies [8]. For other characteristics, including hor-
monal status in blood (e.g. testosterone), no differences 
were observed between COPD and Healthy (Table 4).
Table 2 Baseline characteristics of m. vastus lateralis for COPD and Healthy
COPD, participants diagnosed with chronic obstructive pulmonary disease; Healthy, healthy control participants. Data presented as mean (SD), and sex-adjusted 
estimated mean differences between study clusters (95% CI). Alpha level at p < 0.05
COPD Healthy Sex-adjusted estimated difference
COPD – Healthy (95% CI) P-value
Cross-sectional area (µm2)
 Type I 4614 (1088) 3720 (951) 449 (70, 827) 0.020*
 Type II 3639 (1235) 3059 (1121) 182 (− 118, 482) 0.232
Myonuclei per fiber
 Type I 2.2 (0.9) 2.1 (0.9) − 0.1 (− 0.4, 0.2) 0.357
 Type II 2.1 (0.7) 1.9 (0.7) − 0.1 (− 0.3, 0.2) 0.504
Myonuclear domain (cross sectional area/nuclei per fiber)
 Type I 2292 (585) 1928 (1030) 360 (107, 613) 0.006*
 Type II 1775 (529) 1740 (1049) − 62 (− 316, 191) 0.628
Fiber type proportion (%)
 Type I 52 (15) 65 (14) − 16 (− 24, − 9)  < 0.001*
 Type IIA 32 (12) 23 (11) 10 (4, 16) 0.001*
 Type IIX 13 (7) 9 (6) 5 (1, 9) 0.007*
 Type IIA/IIX 3 (2) 2 (2) 0.7 (− 0.4, 1.9) 0.159
Total RNA (ng / ml) 477 (103) 504 (106) − 20 (-59, 18) 0.302
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The efficacy of the resistance training intervention: COPD 
vs Healthy
For both COPD and Healthy, the training interven-
tion was associated with low drop-out rates (n = 4, ~ 5%; 
COPD, n = 2), high adherence to the protocol (COPD, 
97%; Healthy, 98%; measured as the average number of 
training sessions completed), progressive increases in 
training volume (Fig. 2), and robust increases in muscle 
strength per training session (e.g. 1RM knee extension, 
0.9%  .  session−1/0.8%  .  session−1, COPD/Healthy; 1RM 
leg press, 1.4% .  session−1/1.3% .  session−1). The habitual 
dietary intake was similar between COPD and Healthy, 
with protein intake being 1.2 (0.3) and 1.3 (0.4) g  .  kg−1 . 
 day−1, respectively, complying with current guidelines 
[44]. The vitamin  D3 supplementation RCT of the project 
did not enhance or affect training-associated changes for 
any of the primary or secondary outcome measures [22].
Muscle strength, muscle mass, muscle quality and one‑legged 
endurance performance
Overall, COPD showed larger training-associated 
increases in lower-body muscle strength and mass 
compared to Healthy (the two legs/training modalities 
combined), measured as relative changes in combined 
factors from baseline (Fig. 4A), with no difference being 
observed for numeric changes (Fig.  4A). COPD and 
Healthy showed similarly scaled improvements in muscle 
quality and one-legged endurance performance (Fig. 4A). 
Within the COPD cluster, worsening of lung function (i.e. 
decreasing predicted  FEV1 values) was associated with 
larger numeric and relative increases in muscle mass, as 
well as larger relative improvements in maximal muscle 
strength, with no such relationship being observed for 
muscle quality or one-legged endurance performance 
(Table  5). Neither of the four core outcome domains 
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Fig. 3 Whole-genome transcriptome analyses of m. vastus lateralis in COPD and Healthy (COPD, n = 19; Healthy, n = 34). At baseline, numerous 
genes were differentially expressed between COPD and Healthy. In A, differences in gene expression between COPD and Healthy are presented 
with leading edge genes (i.e. genes that contributes to the enrichment score) from two gene sets identified as differentially expressed between 
COPD and Healthy from gene enrichment analyses (oxidative phosphorylation and myogenesis; see Table 3). In B, average fold differences 
(COPD-Healthy) of genes contributing to baseline differences in oxidative phosphorylation and myogenesis gene sets are shown as individual 
data points, and violin plots shows the distribution of all leading edge genes from each gene set. C displays the average development of each 
gene set over time, where the dotted line indicates the mean fold change of all genes contributing to the differential change over time between 
COPD and Healthy. COPD displayed larger increases in expression of genes relating to oxidative phosphorylation after 3½ weeks of training, and 
more pronounced decreases in genes associated with myogenesis to after the training intervention (Post-RT; see Table 3). FDR, false discovery 
rate-adjusted p-value
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performance) were differentially affected by resistance 
training load (neither in COPD nor in Healthy), suggest-
ing that 30RM training is an effective alternative to 10RM 
training in older individuals (Fig.  4B, C). Of note, the 
comparisons between 10 and 30RM training responses 
may have been confounded by the so-called cross-educa-
tion effect, whereby training of one limb affects functional 
and biological characteristics of the contralateral limb. 
However, the true existence of such cross-education 
effects remains disputed, and if it does exist, its impact is 
likely restricted to neuromuscular functionality [45, 46], 
with no apparent effects on muscle biological measures 
such as mRNA abundance [45], mitochondrial content 
[47, 48], capillarization [49], muscle protein synthesis 
[50] or muscle hypertrophy [51, 52]. In accordance with 
this, the cross-education effect may have affected meas-
ures of muscle strength and one-legged endurance per-
formance in the present study. Importantly, however, 
several measures were implemented into the study pro-
tocol to minimize its impact, including extensive famil-
iarization to training and physical testing (e.g. baseline 
muscle strength was measured after 3 ½ weeks of intro-
duction to training and was preceded by 3–5 familiariza-
tion sessions to muscle strength testing) [22].
Overall, COPD showed marked and hitherto unrec-
ognized responsiveness to resistance training in respect 
of improvements in muscle strength, muscle mass, mus-
cle quality and one-legged endurance performance, 
contradicting previous suggestions of a negative impact 
of co-morbidities such as low cardiorespiratory fitness 
and chronic low-grade systemic inflammation [8, 24]. 
Indeed, a more severe COPD diagnosis was associated 
with larger increases in muscle mass and muscle strength 
improvements. This observation cannot be readily 
explained by baseline differences between the COPD par-
ticipants (e.g. baseline muscle mass vs predicted  FEV1, 
p = 0.998; baseline muscle strength vs predicted  FEV1, 
p = 0.646). The marked training responsiveness in COPD 
was presumably also decoupled from initial differences in 
physical activity habits between study clusters, as COPD 
and Healthy showed similar characteristics regarding 
these measures (Table  1), though some caution is war-
ranted for interpretation of such self-reported recall 
questionnaire results [53].
Cycling and functional performance
COPD and Healthy showed pronounced and similarly 
scaled training-associated improvements in whole-
body endurance performance, measured as changes 
from baseline, including 6-min step test performance, 
1-min sit-to-stand performance and maximal workload 
achieved during two-legged cycling (Fig.  5). Surpris-
ingly, COPD and Healthy also showed similar changes 
in performance for these outcome measures in numeric 
terms, with exception of 6-min step test performance, 
for which Healthy showed larger improvements 
Table 3 Comparison of Hallmark gene sets identified in whole-genome transcriptome data between COPD (n = 19) and Healthy 
(n = 34), assessed at baseline and as resistance training-associated changes
*Consensus significance indicates agreement between directional (GSEA) and non-directional (Rank) hypothesis test of overrepresentation (see methods for details). 
†Indicates number of identified genes in the gene set and total number of genes in the gene set in parentheses. ‡Rank-based enrichment test, based on minimum 
significant difference (MSD), identifies gene sets that are overrepresented among top-ranked genes without a directional hypothesis. § Fraction of genes in gene set 
with unadjusted 95% CI not spanning zero, i.e. MSD > 0. || Gene-set enrichment analysis (GSEA) tests for overrepresentation among top and bottom genes based on 
 Log2 fold differences or changes × -log10(P-values) in comparing differences at baseline or changes from baseline between COPD and Healthy. A positive normalized 
enrichment score (NES) indicate gene set with higher expression in COPD than Healthy; negative NES indicate gene set with lower expression at respective time-
points. ** Number of genes in leading edge (LE, genes that contributes to the enrichment score) with the fraction of leading edge genes with unadjusted 95% CI not 
spanning zero. ∆ change score
Comparison Gene set Significance 
category*
Set  size† Rank 
P-value‡
% MSD >  0§ GSEA 
P-value||
NES LE** Log2 fold 






Consensus 190 (200) 0.007 36.8%  < 0.001 − 2.10 70 (94.3%) − 0.24 (− 0.45, 
− 0.13)
Myogenesis Rank 163 (200)  < 0.001 33.7% 0.417 1.21 45 (75.6%) 0.46 (0.19, 1.5)






GSEA 115 (200) 0.956 7.8% 0.014 1.71 20 (35%) 0.39 (0.13, 0.76)
Oxidative phos-
phorylation
GSEA 190 (200) 0.999 1.1% 0.009 1.69 83 (2.4%) 0.11 (0.05, 0.39)
Pancreas beta 
cells






Myogenesis Consensus 163 (200)  < 0.001 42.3%  < 0.001 − 1.52 68 (85.3%) − 0.5 (− 1.13, 
− 0.26)
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(COPD, 6 steps; Healthy, 17 steps; ∆11 steps, p = 0.009; 
Fig. 5), arguably related to the considerable cardiorespi-
ratory demand of this test, leaving COPD with morbid-
ity-specific restraints. Corroborating with this, within 
the COPD cluster, there was no association between 
the severity of the COPD diagnosis and resistance 
training-induced changes in whole-body endurance 
performance (Table  5). For other performance indices 
such as cycling economy and gross efficiency, which 
were measured using a one-legged cycling protocol, 
COPD showed larger relative improvements compared 
to Healthy (∆4% (COPD – Healthy) for both cycling 
economy and gross efficiency, Fig. 5). For these indices 
of cycling performance, COPD, but not Healthy, dis-
played benefits of 10RM compared to 30RM training 
(Fig. 5), corresponding to previously observed effects of 
heavy resistance training in healthy, young individuals 
[54].
Together, these observations reiterate on the sub-
stantial benefits of resistance training for subjects with 
COPD, even for performance measures that pose large 
whole-body metabolic demands, which has previously 
Table 4 Effects of the training intervention on body composition and blood variables in COPD and Healthy, assessed as changes from 
baseline to after completion of the study (per study cluster) and as differential changes between study clusters
Body composition analyses, n COPD = 19, n Healthy = 48; blood analyses, n COPD = 20, n Healthy = 58. *significant difference between COPD and Healthy at baseline; 
†only men were included in testosterone analysis; ↓significant decrease from baseline to post RT (after 13 weeks of resistance training); ↑significant increase from 
baseline to post RT. Alpha level at p < 0.05. Data are presented as means (SD)
COPD Healthy ∆ COPD vs∆ 
Healthy (P 
value)Baseline Post RT Time effect 
(P < 0.05)
Baseline Post RT Time effect 
(P < 0.05)
Dual-energy x-ray absorptiometry
 Whole-body bone mineral density (g .  cm2) 1.13 (0.21) 1.13 (0.21) No 1.15 (0.16) 1.14 (0.15) No 0.119
 Total lean mass (kg) 46.7 (9.9) 47.6 (10.2) Yes ↑ 48.1 (10.0) 48.6 (10.0) Yes ↑ 0.395
 Appendicular lean mass (kg) 20.3 (5.3) 20.9 (5.5) Yes ↑ 21.6 (5.0) 21.9 (5.0) Yes ↑ 0.166
 Total fat mass (kg) 26.4 (11.7) 26.3 (11.5) No 25.3 (9.3) 24.4 (9.2) Yes ↓ 0.068
 Visceral fat (kg) 1.59 (1.18) 1.56 (1.21) No 1.12 (0.98) 1.01 (0.81) Yes ↓ 0.138
Inflammation
 C-reactive protein (mg .  L−1) 3.4 (5.0) 3.6 (4.0) No 1.7 (2.5) 1.8 (3.5) No 0.934
Hormones
 Cortisol (nmol .  L−1) 307 (130)* 310 (109) No 369 (88) 372 (99) No 0.861
 Growth hormone (µg .  L−1) 1.4 (2.8) 1.4 (3.1) No 1.1 (1.7) 1.3 (1.6) No 0.837
 IGF-1 (nmol . L −1) 15.7 (4.2) 15.0 (4.5) No 14.4 (3.2) 13.6 (3.1) Yes ↓ 0.977
 Testosterone (nmol .  L−1)† 11.2 (4.4) 11.4 (4.2) No 11.9 (3.3) 12.4 (4.2) No 0.938
 Sex-hormone binding globulin (nmol .  L−1) 60 (33) 60 (34) No 60 (22) 60 (21) No 0.488
 Androstenedione (nmol .  L−1) 3.3 (2.4) 3.3 (2.4) No 3.8 (2.7) 3.8 (2.4) No 0.984
 Parathyroid hormone (pmol .  L−1) 5.7 (2.6) 6.0 (3.3) No 5.0 (2.2) 5.2 (1.9) No 0.870
Lipid profile variables
 Triglycerides (mmol .  L−1) 1.2 (0.5) 1.1 (0.5) No 1.2 (0.5) 1.1 (0.6) Yes ↓ 0.661
 HDL (mmol .  L−1) 1.6 (0.6) 1.7 (0.5) No 1.7 (0.5) 1.7 (0.5) No 0.523
 LDL (mmol .  L−1) 2.8 (1.0)* 2.8 (1.0) No 3.4 (1.0) 3.3 (0.8) No 0.775
Iron biology variables
  Fe2+ (µmol .l  L−1) 18 (7) 18 (6) No 18 (6) 18 (5) No 0.410
 Transferrin (g .  L−1) 2.66 (0.44)* 2.67 (0.45) No 2.41 (0.27) 2.38 (0.29) No 0.563
 Ferritin (µg .  L−1) 113 (92) 90 (81) Yes ↓ 139 (79) 133 (68) No 0.089
Calcium status
 Calcium (mmol .  L−1) 2.4 (0.1) 2.4 (0.1) No 2.4 (0.1) 2.4 (0.1) No 0.865
 Albumin-corrected calcium (mmol .  L−1) 2.3 (0.1) 2.3 (0.1) No 2.3 (0.1) 2.3 (0.1) No 0.802
Tissue damage variables
 Aspartate transaminase (units .  L−1) 27 (9) 24 (6) No 26 (21) 26 (7) No 0.807
 Creatine kinase (units .  L−1) 112 (69) 123 (71) No 95 (47) 125 (72) Yes ↑ 0.523
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been suggested to be irresponsive to such training [55]. 
As such, it seems plausible that the observed improve-
ments in 6-min step test performance, 1-min sit-to-stand 
performance and two-legged cycling were associated 
with improvements in work economy/gross efficiency 
and muscle strength, as neither COPD nor Healthy 
showed training-associated changes in maximal oxygen 
consumption (Fig.  5), with improvements in anaerobic 
capacity being a potential contributor (not measured).
Fig. 4 Effects of the resistance training intervention on lower-body muscle strength (COPD, n = 18; Healthy, n = 50), lower-body muscle mass 
(COPD, n = 19; Healthy, n = 47), one-legged endurance performance (COPD, n = 15; Healthy, n = 49) and lower-body muscle quality (COPD, 
n = 18; Healthy, n = 38) in COPD and Healthy. Each outcome domain is represented by a combined factor, computed from various performance 
assessments, as defined in the upper panel of the figure and previously described [22]. A presents comparison of overall training effects between 
COPD and Healthy, measured as relative changes from baseline to after the resistance training intervention (per study cluster; left panel) and as 
relative and numeric differences in change scores between study clusters (right panels). In these analyses, high- and low-load resistance training 
(10RM and 30RM, respectively) were combined, warranted by the lack of differences between training load conditions in (B, C). COPD showed 
greater relative changes in muscle strength and muscle mass than Healthy. B, C presents comparison of effects of 10RM and 30RM resistance 
training in COPD (B) and Healthy (C) (i.e. per study cluster), measured as relative changes from baseline to after the intervention (left panels) and 
as relative and numeric differences in change scores between load conditions (right panels). #statistically different effects of resistance training 
between COPD and Healthy. Data are presented as means with 95% confidence limits
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Muscle fiber characteristics
Whereas COPD and Healthy displayed similar increases 
in type II fiber CSA in m. vastus lateralis in response to 
resistance training (COPD, 18%; Healthy, 24%; ∆-6%, 
p = 0.438; Fig.  6, upper panel), only Healthy showed 
increases in type I fiber CSA (16%), with no statisti-
cal difference being observed between study clusters. 
For Healthy, the increase in CSA was accompanied 
by increased myonuclei  .  fiber−1 in both fiber types 
(36%/25% for type I/II; Fig. 7), leading to decreased myo-
nuclear domain size estimates in type I fibers (-10%, 
Fig. 7). For COPD, no such effects were observed (Fig. 7). 
Despite the lack of difference between the two study clus-
ters for these variables, the data hints at blunted plasticity 
of type I muscle fibers in COPD only, potentially relating 
to their altered biological characteristics at baseline or to 
blunted myonuclear accretion. Interestingly, in sub-anal-
yses, the blunted type I responses in COPD seemed to be 
specific to 10RM training, with a tendency towards supe-
rior responses to 30RM training (10RM, -3%; 30RM, 19%; 
∆22%, p = 0.060; Fig.  6, middle panel). Such a phenom-
enon is supported by previous observations in responses 
to blood-flow-restricted low-load training [56], which 
arguably is mimicked by COPD subjects during low-load 
training, as they display inherent lowering of oxygen sat-
uration in blood.
Both COPD and Healthy displayed training-associ-
ated reductions in type IIX muscle fiber proportions 
(Fig.  7). While this reduction was more pronounced in 
COPD when measured at the protein level (immunohis-
tochemistry), it was more pronounced in Healthy when 
measured at the mRNA level, suggesting differential 
orchestration of muscle fiber shifts between study clus-
ters, possibly relating to their inherently different muscle 
fiber proportions at baseline.
Muscle RNA content
In general, COPD and Healthy showed similar increases 
in ribosomal RNA abundance per unit muscle tissue 
weight, measured as both total RNA and rRNA expres-
sion, and measured after both 3½ week (1.19/1.29 and 
1.16/1.16 fold increases, total RNA/rRNA abundances) 
and after finalization of the training intervention 
(1.12/1.05 and 1.19/1.17 fold increases) (Fig.  8). While 
these changes in ribosomal RNA content were generally 
similar between COPD and Healthy, a few noteworthy 
differences were evident, including a more robust early 
increase in 45s pre-rRNA abundance in COPD (Fig.  8) 
and a trend towards reduced changes in response to 
13  weeks training in COPD, which led to the absence 
of time effects for all rRNA species. The early increases 
in ribosomal content seen in both COPD and Healthy 
resemble those typically seen after similar interventions 
in untrained young individuals [26], and may be impor-
tant for muscle growth capabilities over the entirety of 
the study period [26, 57], accommodating increases in 
protein synthesis capacity, thus potentially contribut-
ing to the pronounced muscular responses to resistance 
training seen in both study clusters.
In both COPD and Healthy, resistance training led 
to marked changes in mRNA transcriptome profiles, 
with 499 and 312 differentially expressed genes being 
observed after 3½ and 13 weeks of resistance training, 
Table 5 Simple linear regression analyses on the relationship between training response and lung function in COPD participants
FEV1predicted, predicted forced expiratory volume in first second; r, Pearson’s r; P, P-value
Analysis n Slope (95% CI) Intercept (95% CI) r P
Change in muscle strength vs  FEV1predicted
 % change 18 − 0.3 (− 0.6, 0.0) 34.8 (16.8, 52.9) − 0.504 0.033
 Numeric change 18 − 0.001 (− 0.003, 0.001) 0.121 (0.017, 0.225) − 0.303 0.222
Change in muscle mass vs  FEV1predicted
 % change 19 − 0.3 (− 0.4, − 0.1) 21.4 (12.1, 30.7) − 0.624 0.004
 Numeric change 19 − 0.002 (− 0.003, 0.000) 0.127 (0.068, 0.186) − 0.603 0.006
Change in muscle quality vs  FEV1predicted
 % change 18 − 0.1 (− 0.4, 0.2) 12.6 (− 4.2, 29.4) − 0.141 0.577
 Numeric change 18 0.000 (− 0.002, 0.002) 0.063 (− 0.060, 0.186) − 0.038 0.881
Change in one-legged endurance performance vs  FEV1predicted
 % change 15 0.3 (− 0.4, 1.0) 8.5 (− 32.8, 49.7) 0.249 0.371
 Numeric change 15 0.001 (− 0.001, 0.002) 0.006 (− 0.066, 0.079) 0.282 0.308
Change in whole-body endurance performance vs  FEV1predicted
 % change 17 − 0.2 (− 0.6, 0.3) 17.7 (− 7.8, 43.1) − 0.211 0.416
 Numeric change 17 0.000 (− 0.001, 0.001) 0.023 (− 0.042, 0.089) 0.012 0.963
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Fig. 5 Comparison of the effects of the resistance training intervention on whole-body endurance performance in COPD and Healthy, presented 
as relative changes from baseline (per study cluster; A) and as relative and numeric differences in change scores between study clusters (B and 
C, respectively). Endurance measures included maximal oxygen consumption (V̇O2max,  cl
.  min−1; COPD, n = 15; Healthy, n = 54) and maximal 
workload (watts; COPD, n = 18; Healthy, n = 55) achieved during two-legged cycling, cycling economy  (cl.  min−1; COPD, n = 15; Healthy, n = 54) and 
gross efficiency measured during submaximal one-legged cycling, the number of steps achieved during 6-min step test (COPD, n = 18; Healthy, 
n = 57) and the number of sit-to-stands achieved during a 1-min sit-to-stand test (COPD, n = 19; Healthy, n = 56). COPD showed greater relative 
improvements in cycling economy and gross efficiency. For these outcome measures, COPD, but not Healthy, displayed benefits of high-load 
training (10RM) compared to low-load training (30RM) (D and E). Healthy showed greater numeric improvement in the number of steps achieved 
during the 6-min step test. COPD and Healthy showed similar relative and numeric training-associated changes in the whole-body endurance 
performance factor. #statistically different response to resistance training between study clusters. ‡statistically different response to 10RM and 30RM 
resistance training in study cluster. Data are presented as means with 95% confidence limits
Fig. 6 Effects of the resistance training intervention on cross-sectional area of muscle fiber types I and II in m. vastus lateralis in COPD (n = 18) and 
Healthy (n = 55). A presents comparison of overall training effects on fiber CSA between COPD and Healthy, measured as relative changes from 
baseline to after the training intervention (per study cluster; left panel) and as relative differences in change scores between study clusters (right 
panel). In these analyses, high- and low-load resistance training (10RM and 30RM, respectively) were combined, warranted by the lack of significant 
differences between training load conditions in (B, C), though COPD tended to show higher efficacy of 30RM resistance training for changes in 
fiber type I CSA. B, C presents comparisons of effects of 10RM and 30RM resistance training on fiber CSA in COPD (B) and Healthy (C) (i.e. per study 
cluster), measured as relative changes from baseline to after the training intervention (left panels) and as relative and numeric differences in change 
scores between load conditions (right panels). Data are presented as means with 95% confidence limits
(See figure on next page.)
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Fig. 6 (See legend on previous page.)
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respectively (for general information about transcrip-
tomic responses, see Mølmen et  al. [22]). Overall, at 
the single-gene level, no transcripts showed differential 
responses to training between the two study clusters, 
neither at 3½ weeks nor at 13 weeks, despite clear dif-
ferences in transcriptome profiles at baseline (Fig.  3A 
and Additional file  1: Table  S2). In contrast, enrich-
ment analyses revealed traces of differential changes 
(Fig. 3C, Table 3 and Additional file 1: TableS 3), with 
COPD showing more pronounces increases in expres-
sion of genes relating to oxidative phosphorylation after 
3½ weeks (GSEA), and, in particular, more pronounced 
decreases in genes associated with myogenesis after 
13  weeks (consensus) (Fig.  3C, Table  3). Interestingly, 
as these two gene sets represented the most prominent 
differences between COPD and Healthy at baseline 
(Fig.  3A, B), and as resistance training led to direc-
tional changes that mitigated these differences, train-
ing arguably shifted the COPD phenotype in a healthy 
direction.
Blood and health‑related outcomes
Overall, COPD and Healthy showed similar training-
associated increases in whole-body and appendicular 
lean mass (Table 4). This was accompanied by increased 
appendicular skeletal muscle mass index relative to the 
sex-specific mean of young, healthy adults (COPD, from 
84 to 86%; Healthy, from 95 to 97%), suggesting that 
the intervention was effective for reversing age-related 
decline in muscle mass. For blood variables such as mark-
ers of systemic inflammation and hormone, lipid and 
iron biology, no noteworthy effects were observed of the 
intervention, nor were any differential changes observed 
between COPD and Healthy (Table 4).
Lung function
For COPD, the training intervention did not affect any of 
the lung function variables (Table 6), implying no effects 
on this core epidemiological trait. This seems reasonable 
given the irreversible nature of the respiratory impair-
ments of COPD, contradicting the beneficial effects 
observed in Hoff et al. [14] In contrast, for Healthy, the 
intervention was associated with reduced FVC and  FEV1 
(−  2.7% and −  1.5%, respectively). Rather than being a 
consequence of the intervention protocol per se, this may 
be due to a general age-related decline, as the magnitude 
of the changes resemble those seen in corresponding age 
cohorts over a similar time frame [58].
Health‑related quality of life
For COPD, the intervention was associated with marked 
improvements in several aspects of health-related qual-
ity of life (Table 7). These included reduced experience of 
limitations of physical functioning and improved social 
function and mental health, with only marginal effects 
being seen in Healthy. While these changes of course may 
be directly related to the resistance training intervention, 
they may also be related to other aspects of the study 
protocol, such as performing training sessions in a social 
setting and the close follow-up each participant received 
from study personnel. As the intervention was conducted 
without a control group (not receiving the intervention 
protocol), caution is warranted for interpretation of these 
data.
Concluding remarks
COPD-related pathophysiologies, such as reduced tes-
tosterone [4], vitamin D [5] and oxygen saturation levels 
[7, 59] in blood, and elevated levels of low-grade inflam-
mation [8], are generally believed to drive metabolism 
into a chronic catabolic state [4, 7, 9]. This has been sug-
gested to lead to impaired responses to lifestyle inter-
ventions such as resistance training [7, 60], which are 
essential measures for preventing and treating disease-
related reductions in skeletal muscle mass and strength, 
counteracting escalation into serious conditions such as 
pulmonary cachexia [17]. Despite this general belief, the 
(See figure on next page.)
Fig. 7 Comparisons of the effects of the resistance training intervention on changes in myonuclei per fiber and myonuclei domain in muscle 
fiber types I and II (A, B; COPD, n = 11; Healthy, n = 34), and on changes in muscle fiber type proportions in COPD and Healthy, measured using 
immunohistochemistry (C–E; COPD, n = 17; Healthy, n = 51)) and qPCR (gene family profiling-normalized myosin heavy chain mRNA expression, 
F–H; COPD, n = 19; Healthy, n = 55), as previously described [26, 75]. Myonuclei domain was calculated as mean fiber cross-sectional area divided 
by myonuclei per fiber. For myonuclei per fiber and myonuclei domain in muscle fiber types I and II, comparisons are presented as relative changes 
from baseline to after the training intervention (per study cluster; A) and as relative differences in change scores between study clusters (B). For 
muscle fiber type proportions, data are presented as adjusted values at baseline and after the training intervention (Post RT), and results are 
presented as the effect of the training intervention for the study clusters combined and its interaction with study clusters (C–H). For myonuclei 
variables, no training-associated differences were observed between study clusters. Both COPD and Healthy displayed training-associated 
reductions in proportions of type IIX muscle fibers, measured using both immunohistochemistry and qPCR. Intriguingly, while this reduction was 
greater in COPD when measured at the protein level (immunohistochemistry), it was greater in Healthy when measured at the mRNA level (qPCR), 
indicating differentially regulated muscle fiber shifting in COPD and Healthy. Data are presented as means with 95% confidence limits
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presence of impaired training responsiveness in COPD 
is not backed by experimental data, and there is limited 
de facto evidence for such impairments. To date, a mere 
single study has compared responses between COPD and 
healthy control subjects [18–20], and as such failing to 
lend support to the prevailing view, though being limited 
by a relatively short time span (8 weeks) and a restricted 
selection of outcome variables. In the present study, we 
largely disavow the myth of impaired responsiveness to 
training in COPD, measured as responses to a 13-week 
Fig. 7 (See legend on previous page.)
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whole-body resistance training intervention, conducted 
using an exhaustive follow-up and testing protocol, which 
included extensive test–retest validations (for details, see 
Mølmen et  al. [22]). Whereas COPD participants dis-
played clear and well-known disease-related aberrancies 
compared to Healthy at baseline, including altered skel-
etal muscle characteristics and elevated levels of systemic 
inflammation, they showed similar or superior improve-
ments for virtually every measure of health, performance 
and biology. Specifically, COPD showed greater relative 
improvements in core outcome domains such as lower-
body muscle strength and mass, and similar relative 
improvements in muscle quality, one-legged endurance 
performance and whole-body endurance performance. 
These similarities were also evident in numeric change 
terms, suggesting that the improvements seen in COPD 
was decoupled from the compromised levels at base-
line. Indeed, within the COPD cluster, worsening of 
lung function was associated with larger numeric and 
relative increases in muscle mass, as well as larger rela-
tive improvements in maximal muscle strength. These 
observations were accompanied by similar alterations 
in muscle biology, including changes in hallmark traits 
such as muscle fiber characteristics, rRNA content and 
transcriptome profiles. Together, these data suggest that 
COPD-related etiologies and pathophysiologies do not 
impair responsiveness to resistance training, at least not 
for skeletal muscle characteristics, and at least not in the 
Fig. 8 Effects of the resistance training intervention on total RNA content (A) and rRNA expression (B–F) in m. vastus lateralis of COPD (n = 19) 
and Healthy (n = 55). Data are presented as fold changes from baseline to Week 3½ (Post-intro RT; seven training sessions) and to after the training 
intervention (Post RT; 26 training sessions). Total RNA (A), 18s rRNA (B), 28s rRNA (C), 5.8s rRNA (D) 5s rRNA (E) and 45s pre-rRNA (F) abundances. 
Total RNA- and qPCR-analyses were assessed as per-amounts of tissue weight, as previously described [22, 26]. #statistical difference in fold change 
between COPD and Healthy (alpha level, p < 0.05). Data are presented as means with 95% confidence limits
Table 6 Effects of the training intervention on lung function in COPD (n = 20) and Healthy (n = 58), assessed as changes from baseline 
to after completion of the study (per study cluster) and as differential changes between study clusters
FVC forced vital capacity, FEV1 forced expiratory volume in one second, PEF peak expiratory flow, ∆ change score, ↓significant decrease from baseline to post RT (after 
13 weeks of resistance training). Alpha level at p < 0.05. Values are means with standard deviation
COPD Healthy
Baseline Post RT Time effect 
p < 0.05)
Baseline Post RT Time effect 
(p < 0.05)
∆ COPD vs 
∆ healthy 
(p-value)
FVC (L) 3.3 ± 0.9 3.2 ± 0.9 No 3.6 ± 0.9 3.5 ± 0.8 Yes↓ 0.189
FEV1 (L 
.  sec−1) 1.5 ± 0.4 1.5 ± 0.4 No 2.7 ± 0.7 2.7 ± 0.6 Yes↓ 0.243
FEV1 (% predicted) 56 ± 11 58 ± 13 No 103 ± 16 103 ± 16 No 0.138
FEV1/FVC (%) 47 ± 8 48 ± 10 No 75 ± 6 76 ± 6 No 0.714
PEF (L .  sec−1) 5.0 ± 1.6 5.1 ± 1.6 No 7.8 ± 2.1 7.6 ± 2.2 No 0.238
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enrolled cluster of COPD participants (GOLD grade II-
III) and within the time frame of the current study.
During planning of the study protocol, two strategies 
were implemented to resolve the hypothesized, albeit 
rejected, negative impact of COPD-specific pathophysi-
ologies for the efficacy of resistance training. First, as 
vitamin D insufficiency is common among COPD sub-
jects [5], and has been suggested to contribute to devel-
opment of anabolic resistance [61], dietary habits were 
manipulated to investigate the effects of vitamin  D3 sup-
plementation. Contrary to our hypothesis, vitamin  D3 did 
not enhance responses to resistance training for any of 
the outcome variables [22]. Second, the resistance train-
ing protocol was conducted using two different training 
modalities, 10RM and 30RM resistance training, per-
formed in a contralateral manner. The efficacies of these 
training modalities were initially hypothesized to be dis-
similarly affected by COPD-related pathophysiologies, 
as they convey muscular adaptations through different 
signaling cues in the cellular environment (i.e. mechani-
cal tension vs metabolic perturbation) [62], and may thus 
well be differentially affected by extracellular signaling 
such as inflammation and oxygen availability. While this 
hypothesis was rejected for all core outcome domains, 
with no differences being observed between training 
modalities and no evidence being found for the pres-
ence of impaired training responsiveness, a noteworthy 
observation was made for muscle fiber-specific traits. 
Specifically, in COPD, 10RM training was associated 
with blunted growth of type I muscle fiber CSA, a phe-
nomenon that was not observed for responses to 30RM 
training, suggesting that 30RM offers benefits for mus-
cle fiber type I hypertrophy. In addition to this, 10RM 
was associated with greater improvements in cycling 
economy and gross efficiency in COPD. These observa-
tions warrant further study. Of note, the unilateral resist-
ance-training design was arguably supportive for the 
pronounced resistance-training effects in COPD partici-
pants. By reducing cardiorespiratory demand, and thus 
facilitating higher degrees of muscle activation and mus-
cle mass-specific intensities during exercise compared 
to conventional two-legged resistance exercise [24] this 
seems to translate into larger functional improvements 
for this population [16].
Study limitations. Functional and physiological 
responses to resistance training is not uniform in the 
human population, and covary with individual character-
istics such as genetics, epigenetics and composites of the 
inner physiological milieu [63–65]. For any research pro-
ject that aim to understand the aetiology of such training, 
the interpretation of outcome data is thus a complicated 
task, which is further complicated by our present crude 
understanding of the interplay between the characteris-
tics in question and their associated response patterns. 
While these limitations need to be acknowledged also 
in the current analyses, their presence underlines the 
importance of making study-design decisions that con-
tribute to increase the ecological validity of the research 
project. As an example, in the present study, the advent 
of contralateral training protocols arguably increased the 
resolution of 10RM vs 30RM comparisons by removing 
genetic variability as a source of variation, albeit even 
Table 7 Effects of the training intervention on health-related quality of life in COPD and Healthy, measured using COPD Assessment 
Test (CAT; COPD-only, n = 20) and the 36-item Short Form Health Survey (SF-36; all participants; n COPD = 20, n Healthy = 57), and 
assessed as changes from baseline to after completion of the study (per study cluster; CAT and SF-36) and as differential changes 
between study clusters (SF-36)
*difference between COPD and Healthy at baseline; ↑significant increase from baseline to after the training intervention (Post RT). Alpha level at p < 0.05. Values are 
means with standard deviation
COPD Healthy ∆ COPD vs 
∆ Healthy (P 
value)Baseline Post RT Time effect 
P < 0.05)
Baseline Post RT Time effect 
(P < 0.05)
COPD assessment Test™ 
score (0–40)
16.6 ± 6.8 16.4 ± 6.8 No – – – –
Short Form (36) Health Survey (0–100)
 Physical function* 63 ± 19 67 ± 18 No 90 ± 14 92 ± 12 No 0.321
 Role physical* 43 ± 34 59 ± 37 Yes↑ 87 ± 25 94 ± 18 No 0.226
 Bodily pain 71 ± 27 82 ± 19 Yes↑ 79 ± 21 80 ± 19 No 0.070
 General health* 48 ± 20 56 ± 19 No 75 ± 18 80 ± 12 No 0.208
 Vitality* 52 ± 16 57 ± 13 No 72 ± 18 78 ± 11 Yes↑ 0.509
 Social function* 74 ± 23 84 ± 16 Yes↑ 90 ± 18 94 ± 13 No 0.280
 Role emotional* 65 ± 39 84 ± 26 Yes↑ 93 ± 19 96 ± 15 No 0.059
 Mental health* 77 ± 13 84 ± 13 Yes↑ 86 ± 11 89 ± 8 Yes↑ 0.196
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this perspective may have been affected by additional 
complications, such as the previously discussed cross-
education effect. Furthermore, in any study, it is prudent 
to monitor, and ideally also account for, exogenous fac-
tors that may have impacted the physiological milieu, and 
therefore also training responses. In the present study, 
these included surveillance of lifestyle characteristics 
such as habitual dietary intake, activities of daily living 
and intake of pulmonary medication. For habitual pat-
terns of dietary intake and activities of daily living, we 
observed no difference between study clusters (COPD 
vs Healthy), though it should be acknowledged that the 
collection of these data were performed only once dur-
ing the study, and as such were performed using diary/
questionnaire, making them prone to validity issues and 
warranting caution upon their interpretation [53, 66]. For 
pulmonary medication, the COPD and Healthy clusters 
deviated from each other for disease-related reasons, 
with 19 out of 20 COPD participants reporting intake of 
either  beta2-agonists, muscarinic agonists, or drugs con-
taining a mixture of  beta2-agonists and glucocorticoids, 
as detailed in Table  1. These drugs are known to affect 
muscle biology and functionality in humans [67–70], and 
as such may have influenced the outcome of the study. 
However, the reported medication status of the COPD 
participants corresponds to what is normal for COPD 
subjects in general [71], and as such reflects the popula-
tion intended to be studied.
In conclusion, 13-week resistance training program 
was well-tolerated by subjects with COPD and led to pro-
nounced improvements for a range of health and muscle 
functional and biological variables, resembling or exceed-
ing those seen in Healthy, with some outcome measures 
even showing indices of more beneficial adaptations in 
COPD participants with a more severe diagnosis. COPD 
was thus not associated with impaired responsiveness to 
resistance exercise training, which rather posed a potent 
measure to relieve disease-related pathophysiologies.
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